ENPP1 deficiency program

About BioMarin Pharmaceutical

BioMarin Pharmaceutical is a publicly traded biotechnology company (NASDAQ: BMRN) focused on developing and commercializing innovative medicines for rare genetic diseases. With approximately 3,000 employees worldwide and operations in ~80 countries, the company has built a proven track record of bringing first-in-class therapies to market. Their distinctive approach to drug discovery leverages genetic insights to target underlying molecular mechanisms of disease, resulting in category-defining medicines that address significant unmet medical needs in rare disease communities.

Therapeutic Areas